ECOR

electroCore, Inc. Common Stock

7.25

USD

-1.55

-17.61%

Nov 06, 15:59 UTC -5

Closed

After-Market

7.40

+0.15

+2.11%

electroCore, Inc. Common Stock (ECOR) Earnings

ECOR Earnings Reports

Positive Surprise Ratio

ECOR beat 22 of 34 last estimates.

65%

Next Report

Date of Next Report

Mar 17, 2027

Estimate for Q4 26 (Revenue/ EPS)

$11.55M

-$0.21

Implied change from Q3 26 (Revenue/ EPS)

+19.17%

+61.54%

Implied change from Q4 25 (Revenue/ EPS)

+24.93%

-38.24%

electroCore, Inc. Common Stock earnings per share and revenue

On Nov 04, 2026, ECOR reported earnings of -0.13 USD per share (EPS) for Q3 26, beating the estimate of -0.27 USD, resulting in a 53.07% surprise. Revenue reached 9.69 million, compared to an expected 11.14 million, with a -13.04% difference. The market reacted with a +4.76% price change (close before vs. close after earnings).

Looking ahead to Q4 26, -- analysts forecast an EPS of -0.21 USD, with revenue projected to reach 11.55 million USD, implying an increase of 61.54% EPS, and increase of 19.17% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Cronos Group Inc. Common Share

Report Date

Nov 05, 2026 For Q3 26

Estimate

$0.03

Actual

$0.04

Surprise

+17.65%

Aclaris Therapeutics, Inc.

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.12

Surprise

+28.49%

Protara Therapeutics, Inc. Common Stock

Report Date

Nov 06, 2026 For Q3 26

Estimate

-$0.37

Actual

-$0.35

Surprise

+6.17%

Minerva Neurosciences, Inc

Report Date

Nov 06, 2026 For Q3 26

Estimate

-$0.12

Actual

$1.94

Surprise

+1,629.97%

Organogenesis Holdings Inc. Class A Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.17

Actual

-$0.25

Surprise

-40.06%

ZOETIS INC.

Report Date

Nov 05, 2026 For Q3 26

Estimate

$1.52

Actual

$1.75

Surprise

+14.64%

Dyne Therapeutics, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.92

Actual

-$1.06

Surprise

-15.57%

Amylyx Pharmaceuticals, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.38

Actual

-$0.38

Surprise

+1.04%

Aldeyra Therapeutics, Inc.

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.09

Actual

-$0.06

Surprise

+37.43%

Lipocine Inc.

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.36

Actual

-$0.08

Surprise

+77.91%

FAQ

What were electroCore, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?

For Q3 2026, electroCore, Inc. Common Stock reported EPS of -$0.13, beating estimates by 53.07%, and revenue of $9.69M, -13.04% below expectations.

How did the market react to electroCore, Inc. Common Stock's Q3 2026 earnings?

The stock price moved up 4.76%, changed from $8.40 before the earnings release to $8.80 the day after.

When is electroCore, Inc. Common Stock expected to report next?

The next earning report is scheduled for Mar 17, 2027.

What are the forecasts for electroCore, Inc. Common Stock's next earnings report?

Based on -- analysts, electroCore, Inc. Common Stock is expected to report EPS of -$0.21 and revenue of $11.55M for Q4 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.